Skip to main content

Table 4 Pain response in evaluable patients

From: Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer

Pain outcome Number of subjects (n = 23)
Number experiencing lesion pain at enrollment 48% (11)
Change in lesion pain score at end of treatment assessment  
 Decrease 64% (7)
 No change 9% (1)
 Increase 27% (3)
Change in lesion pain score 15 days post treatment in subjects reporting a decrease at end of treatment (n = 7)  
 Decrease 0% (0)
 No change 29% (2)
 Increase 71% (5)